Article by Marie Powers in BioWorld; Monday, June 10, 2013
Article summary:
Chronic fatigue syndrome (CFS) has been at the center of a vortex of controversy since the FDA handed down a complete response letter on the Toll-like receptor 3 modulator Ampligen (rintatolimod) from Hemispherx Bioscience Inc. – the only drug in development for CFS – despite the impassioned pleas of patients at an Arthritis Advisory Committee meeting in December 2012…
The article describes Biovista’s COSS technology for drug repositioning with references to recent deals and collaborations with the Chronic Fatigue and Immune Dysfunction Syndrome (CFIDS) Association of America, DART Therapeutics Inc., Cempra Inc. and the FDA, among others.
Read the full article here…